Inhibrx Biosciences End Period Cash Flow History
| INBX Stock | USD 134.35 9.83 7.89% |
End Period Cash Flow | First Reported 2017-12-31 | Previous Quarter 153.09 million | Current Value 124.22 million | Quarterly Volatility 96.4 million |
Macro event markers
Latest Inhibrx Biosciences End Period Cash Flow Growth Pattern
| End Period Cash Flow | 10 Years Trend |
|
End Period Cash Flow |
| Timeline |
End Period Cash Flow Trend Statistics
Measured across 10 periods, Inhibrx Biosciences' End Period Cash Flow has a coefficient of variation of 111.5% (wide dispersion driven primarily by directional growth rather than instability). The regression fit of 0.51 reflects a moderate linear trend with partial explanatory power.| Arithmetic Mean | 81,222,699 | |
| Geometric Mean | 39,323,049 | |
| Coefficient Of Variation | 111.55 | |
| Mean Deviation | 75,875,175 | |
| Median | 20,025,000 | |
| Standard Deviation | 90,600,832 | |
| Sample Variance | 8208.5T | |
| Range | 275.8M | |
| R-Value | 0.71 | |
| Mean Square Error | 4306.7T | |
| R-Squared | 0.51 | |
| Significance | 0.0013 | |
| Slope | 12,789,326 | |
| Total Sum of Squares | 131336.2T |
Inhibrx Biosciences End Period Cash Flow History
The series below tracks Inhibrx Biosciences' End Period Cash Flow over 10 periods, from 13.47 million in 2017 to 124.93 million in 2026.| 2026 | 124.93 million | ||
| 2025 | 124.22 million | ||
| 2024 | 152.6 million | ||
| 2023 | 277.92 million | ||
| 2022 | 273.87 million | ||
| 2021 | 131.3 million | ||
| 2020 | 128.66 million | ||
| 2019 | 11.54 million | ||
| 2018 | 2.1 million | ||
| 2017 | 13.47 million |
Correlation of End Period Cash Flow With Other Accounts
Linear correlations between End Period Cash Flow and other accounts within Inhibrx Biosciences' reporting history are shown below. Strong correlations may reflect underlying operational relationships or scaling effects across related metrics.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Begin Period Cash Flow | $152.6 million | $112.32 million | |
| Change In Cash | $-28.38 million | $-26.96 million | |
| Stock Based Compensation | $11.14 million | $15.75 million | |
| Free Cash Flow | $-129.82 million | $-136.32 million | |
| Change In Working Capital | $-7.61 million | $-7.23 million | |
| Total Cashflows From Investing Activities | $-28,000 | $-29,400 |
Methodology, Assumptions & Data Sources
Inhibrx Biosciences's End Period Cash Flow is presented on a quarterly basis for longitudinal analysis. The regression slope and R-squared together indicate whether the directional trend is persistent or episodic. Inhibrx Biosciences' End Period Cash Flow reflects how the company converts operating results into distributable cash flow.
Inhibrx Biosciences inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. Analyst projections are included when active coverage applies. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Vlad Skutelnik, Macroaxis Contributor